missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 30307798

CDK4 Antibody (CL8102) [Janelia Fluor™ 549], Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NBP2-88912JF549

Product Code. 30307798

  • 737.00€ / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

CDK4 Monoclonal antibody specifically detects CDK4 in Human samples. It is validated for Immunohistochemistry,Western Blot,Immunohistochemistry (Paraffin),Immunocytochemistry/ Immunofluorescence
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CDK4
Monoclonal
Janelia Fluor 549
Cell division protein kinase 4, CMM3, cyclin-dependent kinase 4, EC 2.7.11, EC 2.7.11.22, melanoma cutaneous malignant, 3, MGC14458, PSK-J3cell division kinase 4
This antibody was developed using a synthetic peptide derived from P11802, with the exact immunogen sequence remaining proprietary.
0.1 mL
Cancer, Cell Cycle and Replication, Core ESC Like Genes, mTOR Pathway, Protein Kinase, Stem Cell Markers
1019
Store at 4⪚C in the dark.
IgG1
Immunohistochemistry, Western Blot, Immunohistochemistry (Paraffin), Immunocytochemistry/Immunofluorescence
CL8102
50mM Sodium Borate
Mouse
Protein A purified
RUO
Primary
Human
Purified
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.